Wolverine has one particular ability that is wildly controversial in the X-Men fandom, & now, Marvel Comics has decided to ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...

Learning you have a life-changing condition is likely alarming no matter what. But if you have axial spondyloarthritis (axSpA ...

Explore the intriguing findings from the Maszycka Cave in Poland. Discover the evidence of ancient humans being consumed by ...

T he sun is barely rising in rural Burundi when we begin our medical rounds in the pediatric ward. I am an American, ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars ...

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OSPOMYV™ (denosumab-dssb; SB16; 60 mg pre-filled ...

A resident of Rafah, Osama Saleh, went back to his home after the ceasefire and found a skeleton inside. The skull was fractured. Mr Saleh reckons the body lay there for four to five months. "We are ...